More News! Cell and gene therapies, immuno-oncology, NASH and more…

Try as we might, we can’t cover all the fascinating biotech news out there! Here’s a roundup of what didn’t make the cut over the last week.

Policy and legal

  • The Polish biotech Selvita announced it will separate into two separate companies one focusing on its oncology therapeutics pipeline and one on its contract research business.
  • French bioplastics company Carbios was granted a US patent for its PET plastic recycling technology.
  • MaSTherCell, a cell and gene therapy company in Belgium, announced it will open a large new commercial manufacturing facility for cell & gene therapies, which is expected to open in 2021.



  • Dutch immuno-oncology biotech Glycostem Therapeutics will partner with Phio Pharmaceuticals to make novel anti-cancer drugs using the US-biotech’s RNAi technology ands natural killer cells.
  • Belgian Barc Labs and Spanish OWL Metabolics will partner to combine lab services and metabolic technology to help develop new therapeutics for the liver condition non-alcoholic steatohepatitis.
  • French Transgene and Swedish BioInvent will extend an existing collaboration to develop oncolytic viruses for treating solid tumors.


  • University of London spin-out Domainex, along with researchers in Belfast, has discovered new anticancer candidate drugs that target a protein called FLIP that could be used to treat blood, breast and lung cancer.

Regulations and funding

  • Irish and English biotech partners Valitacell and Solentim obtained €3.5M funding to help develop new biologics and cell therapies.
  • Kymriah, a CAR T-cell therapy developed by Novartis, has been given marketing approval in Japan, the first such therapy to be approved in Asia.
  • German biotech Cytena received €3M in series A funding to progress its single cell isolation and analysis technology.
  • Synerkine Pharma, a Dutch biotech focusing on treating chronic pain, closed a €3.3M series A round.
  • UK-Irish Inflazome received more than €890,000 funding from The Michael J. Fox Foundation to go towards its research into treating Parkinson’s disease.

Clinical trials

  • Italian biotech Cassiopea announced positive phase III results, for both efficacy and safety, for its acne treatment clascoterone when taken for up to a year.

Images via E. Resko

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.